Exploring the Link Between LSD and Anxiety

Dr. Joseph Mercola - Take Control of Your Health

Briana Mercola

Alternative Health, Health & Fitness

4.6 • 1.6K Ratings

🗓️ 15 November 2025

⏱️ 8 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

LSD shows promise for anxiety treatment. A Phase 2b clinical trial found that 100 micrograms of MM120 (pharmaceutical LSD) reduced anxiety significantly with lasting effects
Study results were encouraging. Researchers noted that 65% of participants experienced clinical response at optimal dosing, with 47.5% achieving remission that sustained through 12 weeks of follow-up
Safety profile was manageable. Most side effects occurred during dosing sessions and resolved quickly, with visual changes and nausea being most common under medical supervision
Note that LSD remains illegal. It is currently classified as Schedule I controlled substance, accessible only through approved clinical trials, with results of Phase 3 trials expected by 2026
In the meantime, natural anxiety alternatives exist. Breathing techniques like nasal breathing, horizontal breathing patterns, and controlled breathing practices can help manage anxiety symptoms without medication

Transcript

Click on a timestamp to play from that location

0:00.0	What if one carefully supervised dose could lower your anxiety for months without daily pills?
0:06.0	Welcome to Dr. Mercola's cellular wisdom. Stay informed with quick, easy-to-listen
0:11.2	summaries of our latest articles, perfect for when you're on the go. No reading required.
0:15.8	Subscribe for free at Mercola.com for the latest health insights.
0:20.1	Hello and welcome to Dr. Mercola's Cellular Wisdom.
0:22.6	I'm Ethan Foster, and today we're examining new clinical evidence on
0:26.6	M-M-120, a pharmaceutical form of LSD, and what it may mean for generalized anxiety disorder.
0:34.6	I'm Alara Sky. We'll lay out the phase 2B trial design, the dose that worked
0:40.1	best, how long the benefits lasted, safety details, current legality, and practical breathing
0:46.9	strategies you can use right now while this research moves forward. The headline finding is
0:52.3	straightforward. In a multi-center, double-blind, placebo-controlled phase
0:57.5	two, B study of adults with moderate to severe generalized anxiety disorder, a single 100-microgram dose of M,
1:05.9	M1-2. Zero produced significant reductions in anxiety with effects that persisted to week 12.
1:12.6	Researchers reported a clinical response in about 65% at this dose and remission in 47.5%.
1:20.1	To put the trial in context, this follows earlier Phase 1 work on MM120 and FDA permission to proceed to phase two testing. The phase 2B study
1:31.7	enrolled 198 participants aged 18 to 74 across 22 U.S. outpatient research sites. Everyone
1:40.0	met the threshold for moderate to severe anxiety on the Hamilton anxiety rating scale,
1:44.9	or HAMA, with scores of 20 or higher at baseline.
1:50.3	Participants were randomized to one of five arms, placebo or MM, 120 at 25, 50, 100, or 200 micrograms.
2:04.6	The primary endpoint was change in ham A score at four weeks, where a 2.5 point drop is considered clinically meaningful.
2:08.6	Response was defined as a 50% or greater reduction.
2:11.6	Remission as a ham. A score of 7 or less.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Briana Mercola, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Briana Mercola and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.